Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ERX-41, as a novel oral therapeutic agent that may have utility in treating multiple solid cancers, including triple negative breast cancer, glioblastoma, ovarian and pancreatic cancers.
Lead Product(s): ERX-41
Therapeutic Area: Oncology Product Name: ERX-41
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022